Adherium Limited (ASX: ADR) Webcast Replay
17th August, 2022
Adherium Limited (ASX: ADR) is a global leader in connected respiratory medical devices, with more than 170,000 sold and 180 patents and designs globally.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Rick Legleiter, provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 17th August 2022 at 12pm (AEST).
Join the next The Insider: Meet the CEOs webcast
FEATURED SPEAKER
Rick Legleiter
CEO - Adherium Limited (ASX: ADR)
Adherium provides connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Founded in 2001 and listed on the ASX in 2015, the company’s strategy is focused on the digital health landscape – a US$34 billion market opportunity. Adherium’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients’ use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and Chronic Obstructive Pulmonary Disease (COPD), and reducing healthcare costs. In 2021, Adherium was awarded a supply contract with AstraZeneca for a bespoke version of its Hailie sensor and software solution for its US study.
